| Drug General Information |
| Drug ID |
D0BH7S
|
| Former ID |
DNC004697
|
| Drug Name |
6-Benzylsulfanyl-9H-purine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C12H10N4S
|
| Canonical SMILES |
C1=CC=C(C=C1)CSC2=NC=NC3=C2NC=N3
|
| InChI |
1S/C12H10N4S/c1-2-4-9(5-3-1)6-17-12-10-11(14-7-13-10)15-8-16-12/h1-5,7-8H,6H2,(H,13,14,15,16)
|
| InChIKey |
ULIQGBPQLPCTAJ-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
mRNA of RAF proto-oncogene serine/threonine-protein kinase |
Target Info |
Inhibitor |
[1]
|
|---|
| Mitogen-activated protein kinase 14 |
Target Info |
Inhibitor |
[1]
|
|
BioCyc Pathway
|
MAP kinase cascade
|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Chemokine signaling pathway
|
|
FoxO signaling pathway
|
|
Sphingolipid signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Vascular smooth muscle contraction
|
|
VEGF signaling pathway
|
|
Focal adhesion
|
|
Gap junction
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Natural killer cell mediated cytotoxicity
|
|
T cell receptor signaling pathway
|
|
B cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
Fc gamma R-mediated phagocytosis
|
|
Long-term potentiation
|
|
Neurotrophin signaling pathway
|
|
Serotonergic synapse
|
|
Long-term depression
|
|
Regulation of actin cytoskeleton
|
|
Insulin signaling pathway
|
|
GnRH signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Estrogen signaling pathway
|
|
Melanogenesis
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Oxytocin signaling pathway
|
|
Alcoholism
|
|
Tuberculosis
|
|
Hepatitis C
|
|
Hepatitis B
|
|
Influenza A
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Colorectal cancer
|
|
Renal cell carcinoma
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
Bladder cancer
|
|
Chronic myeloid leukemia
|
|
Acute myeloid leukemia
|
|
Non-small cell lung cancer
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancerhsa04010:MAPK signaling pathway
|
|
Adrenergic signaling in cardiomyocytes
|
|
Osteoclast differentiation
|
|
Platelet activation
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
RIG-I-like receptor signaling pathway
|
|
TNF signaling pathway
|
|
Leukocyte transendothelial migration
|
|
Retrograde endocannabinoid signaling
|
|
Dopaminergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Shigellosis
|
|
Salmonella infection
|
|
Pertussis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Epstein-Barr virus infection
|
|
NetPath Pathway
|
IL5 Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
EGFR1 Signaling PathwayNetPath_17:IL5 Signaling Pathway
|
|
FSH Signaling Pathway
|
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
B cell activation
|
|
EGF receptor signaling pathway
|
|
Endothelin signaling pathway
|
|
FGF signaling pathway
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
|
Integrin signalling pathway
|
|
Interleukin signaling pathway
|
|
PDGF signaling pathway
|
|
T cell activation
|
|
VEGF signaling pathway
|
|
Ras Pathway
|
|
Angiotensin II-stimulated signaling through G proteins and beta-arrestin
|
|
CCKR signaling map STP00003:Alzheimer disease-amyloid secretase pathway
|
|
Interferon-gamma signaling pathway
|
|
Oxidative stress response
|
|
Parkinson disease
|
|
TGF-beta signaling pathway
|
|
Toll receptor signaling pathway
|
|
p53 pathway feedback loops 2
|
|
p38 MAPK pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Fc-epsilon receptor I signaling in mast cells
|
|
Endothelins
|
|
BCR signaling pathway
|
|
GMCSF-mediated signaling events
|
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
|
CDC42 signaling events
|
|
SHP2 signaling
|
|
mTOR signaling pathway
|
|
IL2-mediated signaling events
|
|
IGF1 pathway
|
|
Ras signaling in the CD4+ TCR pathway
|
|
Ceramide signaling pathway
|
|
ErbB1 downstream signaling
|
|
ErbB2/ErbB3 signaling events
|
|
PDGFR-beta signaling pathway
|
|
p38 signaling mediated by MAPKAP kinases
|
|
Nongenotropic Androgen signaling
|
|
Internalization of ErbB1
|
|
CXCR3-mediated signaling events
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Class I PI3K signaling events mediated by Akt
|
|
Trk receptor signaling mediated by the MAPK pathway
|
|
Downstream signaling in naï
|
|
Regulation of retinoblastoma protein
|
|
Signaling events mediated by focal adhesion kinaseendothelinpathway:Endothelins
|
|
p73 transcription factor network
|
|
p38 MAPK signaling pathway
|
|
Atypical NF-kappaB pathway
|
|
IL4-mediated signaling events
|
|
CD40/CD40L signaling
|
|
IL12-mediated signaling events
|
|
Regulation of p38-alpha and p38-beta
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
FAS (CD95) signaling pathway
|
|
Thromboxane A2 receptor signaling
|
|
Role of Calcineurin-dependent NFAT signaling in lymphocytes
|
|
Glucocorticoid receptor regulatory network
|
|
Rapid glucocorticoid signaling
|
|
Regulation of Androgen receptor activity
|
|
ATF-2 transcription factor network
|
|
IL6-mediated signaling events
|
|
Retinoic acid receptors-mediated signaling
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
EPO signaling pathway
|
|
p53 pathway
|
|
S1P2 pathway
|
|
VEGFR3 signaling in lymphatic endothelium
|
|
FGF signaling pathway
|
|
RAC1 signaling pathway
|
|
PathWhiz Pathway
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Insulin SignallingPW000453:Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Reactome
|
Stimuli-sensing channels
|
|
GP1b-IX-V activation signalling
|
|
CREB phosphorylation through the activation of Ras
|
|
CD209 (DC-SIGN) signaling
|
|
RAF activation
|
|
MAP2K and MAPK activation
|
|
Negative feedback regulation of MAPK pathway
|
|
Negative regulation of MAPK pathwayR-HSA-168638:NOD1/2 Signaling Pathway
|
|
p38MAPK events
|
|
ERK/MAPK targets
|
|
Activation of PPARGC1A (PGC-1alpha) by phosphorylation
|
|
Oxidative Stress Induced Senescence
|
|
CDO in myogenesis
|
|
DSCAM interactions
|
|
ADP signalling through P2Y purinoceptor 1
|
|
Platelet sensitization by LDL
|
|
VEGFA-VEGFR2 Pathway
|
|
activated TAK1 mediates p38 MAPK activation
|
|
Activation of the AP-1 family of transcription factors
|
|
KSRP (KHSRP) binds and destabilizes mRNA
|
|
WikiPathways
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
|
TCR Signaling Pathway
|
|
Senescence and Autophagy in Cancer
|
|
EPO Receptor Signaling
|
|
Regulation of Actin Cytoskeleton
|
|
IL-2 Signaling Pathway
|
|
Insulin Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
MAPK Cascade
|
|
MAPK Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
Signaling of Hepatocyte Growth Factor Receptor
|
|
Kit receptor signaling pathway
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
IL-3 Signaling Pathway
|
|
Cardiac Hypertrophic Response
|
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
|
RAF/MAP kinase cascade
|
|
Iron uptake and transport
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
PDGF Pathway
|
|
Retinoblastoma (RB) in Cancer
|
|
BDNF signaling pathway
|
|
Integrated Pancreatic Cancer Pathway
|
|
Oncostatin M Signaling Pathway
|
|
Corticotropin-releasing hormone
|
|
Interleukin-11 Signaling Pathway
|
|
AGE/RAGE pathway
|
|
TNF alpha Signaling Pathway
|
|
B Cell Receptor Signaling Pathway
|
|
Prostate Cancer
|
|
Signaling Pathways in Glioblastoma
|
|
Endothelin Pathways
|
|
TWEAK Signaling Pathway
|
|
FSH signaling pathway
|
|
Leptin signaling pathway
|
|
Rap1 signalling
|
|
Integrin-mediated Cell Adhesion
|
|
GP1b-IX-V activation signalling
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
IL-5 Signaling PathwayWP75:Toll-like receptor signaling pathway
|
|
Monoamine Transport
|
|
Serotonin HTR1 Group and FOS Pathway
|
|
Interferon type I signaling pathways
|
|
Oxidative Stress
|
|
p38 MAPK Signaling Pathway
|
|
IL-4 Signaling Pathway
|
|
MAP kinase activation in TLR cascade
|
|
Regulation of mRNA Stability by Proteins that Bind AU-rich Elements
|
|
Structural Pathway of Interleukin 1 (IL-1)
|
|
JAK/STAT
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Alpha 6 Beta 4 signaling pathway
|
|
Cardiac Progenitor Differentiation
|
|
Parkinsons Disease Pathway
|
|
TSLP Signaling Pathway
|
|
RANKL/RANK Signaling Pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in leukocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
IL-1 signaling pathway
|
|
Signal amplification
|
|
Platelet homeostasis
|
|
NGF signalling via TRKA from the plasma membrane
|
|
Myogenesis
|
|
DSCAM interactions
|
|
Angiogenesis
|
|
Physiological and Pathological Hypertrophy of the Heart
|
|
Regulation of toll-like receptor signaling pathway
|
| References |
| REF 1 | J Med Chem. 2005 Feb 10;48(3):710-22.Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. |
|---|
